Introduction: Too many patients with moderate to severe psoriasis do not receive adequate treatment. This means a vast
undersupply in the treatment of patients with psoriasis. Only biologics fulfill the whole range of the treatment of psoriasis
– psoriasis does not affect only skin but the whole organism: It is a systemic disease! Between the biologics are evident
differences concerning the effect.
Discussion: Based on broad personal experience in the management of patients with moderate to severe psoriasis new
data from clinical studies with ixekizumab are examined. This contains new data on long-term-efficacy of ixekizumab,
effectiveness in special localizations (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis) as well as
safely data and experience on patients switched to ixekizumab from other biologics. Personal clinical experience is based
on >300 non-selected outpatients with moderate to severe psoriasis, >250 patients on biological therapies, > 50 patients
with ixekizumab.
Conclusions: Focusing on a relevant number of patients switched from secukinumab to ixekizumab due to first or secondary
loss of efficacy significant differences between both IL-17A-inhibitors mainly in terms of efficacy and speed of therapeutic
response are shown. Finally the correlation between PASI-90-/PASI-100 response and significant changes in DLQI are
highlighted.
